The FDA has issued a report on PFAS in cosmetics, and law firm ArentFox Schiff has published an analysis of its key findings, the risks it identifies, and the regulatory implications for the beauty and personal care sector.

For formulators, quality teams and regulatory affairs staff, the report lands at a moment when per- and polyfluoroalkyl substances — the "forever chemicals" used for water resistance, slip and durability in some makeup, skincare and hair products — face tightening restrictions across multiple jurisdictions. The FDA document adds a US federal data point to a debate that has already produced state-level bans and retailer reformulation demands.

What does the report cover?

According to ArentFox Schiff's summary, the report sets out:

• Key findings on the presence and detection of PFAS in cosmetic products
• Risk assessments tied to consumer exposure through cosmetic use
• Regulatory implications for manufacturers, importers and brand owners operating in the US market

The law firm frames the publication as a signal that FDA is consolidating its evidence base on PFAS in cosmetics — a step that typically precedes more concrete regulatory action, whether that takes the form of testing requirements, labeling obligations, or ingredient restrictions.

Why does this matter for compliance teams?

PFAS is not a single ingredient but a family of thousands of synthetic chemicals, which complicates compliance. Brands must audit supply chains not only for intentionally added PFAS — used for film-forming, water repellency and long-wear effects — but also for contamination introduced through raw materials, manufacturing equipment or packaging.

The US picture is fragmented. Several states have already moved to restrict intentionally added PFAS in cosmetics, creating a patchwork of state rules that national brands must track. A federal report from FDA gives the industry a single authoritative reference point, and ArentFox Schiff's analysis positions it as essential reading for anyone mapping exposure across a portfolio.

What should formulators and buyers do now?

The practical consequences flagged by the analysis touch several functions:

• Product development: INCI-level reviews of film-formers, waterproofing agents and long-wear ingredients to identify fluorinated chemistry
• Procurement: supplier certifications on PFAS content in raw materials, including impurity thresholds
• Compliance: gap analysis against the report's findings ahead of any federal follow-up action
• Labeling and claims: preparation for possible disclosure obligations if regulation moves from reporting to restriction

What comes next?

The report itself does not close the question. Its significance lies in what it enables: a documented federal findings base from which FDA could propose further measures, and which state regulators and plaintiffs' attorneys can cite. ArentFox Schiff's takeaways suggest the industry should treat the report as a planning document rather than a final verdict.

Watch for FDA follow-up — comment periods, guidance documents, or formal rulemaking proposals building on the report's findings — as the next concrete data points that will determine the compliance workload for cosmetics manufacturers selling in the US.